hale & tempest generic country markets & biosimilars chesapeake dr. brian w tempest ...
TRANSCRIPT
Hale & Tempest
Generic Country Markets & Biosimilars
Chesapeake
Dr. Brian W Tempest
www.briantempest.com
UK
March 2014
Hale & Tempest
7. Generic Country Markets
Hale & Tempest
Europesource: EGA
Hale & Tempest
Reference Pricing Globally Endemic
Source : Istanbul September 2012
Pharma purchases reduced from 1.7% of GDP to 1.0% of GDP in Turkey
Russia, South Korea & Saudi Arabia health ministries requested Turkish prices
Everybody is referencing everybody else on Pharma prices in Europe
Bulgaria is referencing prices in 17 other countries
Hale & Tempest
Europe – generics take half the volume but a fraction of value sales
Hale & Tempest
EU Chemical Sales
source: Chemistry World September 2013
Hale & Tempest
Open letter to Barroso from the Chairman of INEOS on 7 March 2014
Hale & Tempest
Generic Global Volume Share Source: Sandoz
Hale & Tempest
30 generic packs, >2 years treatment £69200 king size cigarettes £68Source: Generics Bulletin 15 Feb 2013
Hale & Tempest
European Generic Prices Source Ranbaxy
Hale & Tempest
Indian Pharma penetration of the UKsource: FT January 13 2014
Hale & Tempest
Security of Power Supplies in Europesource: Economist 15 April 2014
Hale & Tempest
France Generic Market Source: Generics Bulletin 15 February 2013
Hale & Tempest
US DMFs from Indiasource: Citi Research 2013
Hale & Tempest
Number of USA Para IVs source: Generics Bulletin 14 September 2012, quarter indian
Hale & Tempest
USA Generic Market - Latest Challengessource: Jefferies 10 March 2014
Hale & Tempest
Africa Management source Ranbaxy
Hale & Tempest
Nigeria, South Africa & Angolasource: Economist 12 April 2014
Hale & Tempest
African Factories
Hale & Tempest
Japan Generic Market
source: Citi Research August 2013
Hale & Tempest
Japan Generic Opportunity
Hale & Tempest
Japanese Generic Marketsource: Mint 28 January 2014
Hale & Tempest
Brazil Generic Packs
Hale & Tempest
Brazil Top 10 Generic Cos
Hale & Tempest
Russia 2020 Strategy for Public Health
Hale & Tempest
Russian Market Evolutionsource: Frost & Sullivan 2011
Hale & Tempest
Vaccine Plant to take 1/3 Russian Market source: St Petersburg Times, 16 April 2014
Hale & Tempest
USA Generic Market - Latest Challengessource: Jefferies 10 March 2014
Hale & Tempest
Russia VLS List
Hale & Tempest
Russia 2020 Strategy 90% local manufacture of VLS list
Hale & Tempest
Russia 2020 Strategy 50% local manufacture of all products
Hale & Tempest
New Novartis Plant in St Petersburgsource: Top Emerging Pharmaceutical Markets by Kathlyn Stone
Hale & Tempest
Russia & India – Big Picturesource: ET March 26 2014
Hale & Tempest
Russia & India – Big Picturesource: ET March 26 2014
Hale & Tempest
Indian Pharma in Russia - DRLsource: website, 20 years
Hale & Tempest
Indian Pharma in Russia - Ranbaxysource: RUR, 20 years, 15% MS IMS May 2013, across 56 Regions
Hale & Tempest
Chinese Debt 200% of GDP in 2013source: FT 2 April 2014
Hale & Tempest
Chinese NGOssource: Economist 12 April 2014
Hale & Tempest
China Pharma Industry Capex PlansSource: Stravencom
Hale & Tempest
China Price Cutssource: Jefferies
Hale & Tempest
China API Exports decline by -9%source: Pharmatiimes February 21 2014
Hale & Tempest
Hisun Pfizer Pharmaceuticals Ltdsource: Launch Announcement September 12 2013
Hale & Tempest
Hisun USAsource: website
Hale & Tempest
Hisun USA acquires FDA approved DPIsource: Press Release January 17 2012
Hale & Tempest
Hisun USA acquires FDA approved DPIsource: Press Release January 17 2012
Hale & Tempest
China: Optimistic view of Domestic Marketsource: Jefferies 17 March 2014
Hale & Tempest
China Provincial Tenderssource: Jefferies 17 March 2014
Hale & Tempest
Sino Biopharm strongest domestic pipeline source: Jefferies March 17 2014
Hale & Tempest
Zhejiang Huahai(Novast also received an ANDA for an OC in 2010)
Hale & Tempest
China - Actavis Withdrawssource: Bloomberg January 15 2014
Hale & Tempest
South Africa Generics
Hale & Tempest
Middle East & North Africa
Hale & Tempest
Jordan punches above its Weight
Hale & Tempest
Canada Generic Market Source: Generics Bulletin 15 Feb2013
Hale & Tempest
Myanmar – a new market
Hale & Tempest
8. Biosimilars
Hale & Tempest
Which Way?
Hale & Tempest
Biologics & Small Molecules source: Kozlowski et al., N England J Med, 365:5, 2011
Hale & Tempest
Estimated 2016 sales of Top 20 products Source: Cowen
Hale & Tempest
Biosimilar Share to 2018 source: EvaluatePharma 2012
Hale & Tempest
Monoclonal antibodies $m Source: Synthon
Hale & Tempest
New Biosimilar Company (with Merck)
Hale & Tempest
Korean Pharma in Biosimilars
source: Citi Research August 2013
Hale & Tempest
Biosimilars from China/India Source: New York Times 20 Sep 2011
Hale & Tempest
Biotech Drugs where India has no DMF Source: JGM Volume 6 p333 sep 2009
Hale & Tempest
Biosimilars from IndiaSource: Citi 25 September 2013
•Market opportunity of $1.5b to $2b for US & EU
•More clarity now on regulatory pathways
•OECD -$100m for R&D development of a MAB, $300m-$400m to set up manufacturing capacity of 100,000L with annual R&D at $100m
•Developing Countries - $200m sales potential, $20m R&D per year, manufacturing capacity of 1,000L planned
•India companies will enter emerging markets but use partnerships and alliances for OECD eg DRL
•Developing Countries limited by affordability issues
Hale & Tempest
Biosimilars Key Issue - Interchangeabilitysource: GaBi Journal Biologics & Biosimilars 28 December 2013
Hale & Tempest
Biosimilar Market SizesSource: IMS, FT February 9 2014
•Global Biologics including Big Pharma blockbusters in 2012 is $170 b
•Biosimilars market size in 2012 is $2.5b and in 2020 is estimated at $25b
•VERSUS•cost of manufacturing plant, •cost of clinical trials, •lower hospital tender prices, •no interchangeability, cost of reps, •patient-innovator relationship, •competition from South Korea, •authorised generics
Hale & Tempest
First Herceptin Trastuzumab Biosimilarsource: ET January 14 2014 Rs 40,000 per 440mg vial, Roche halved price at Rs 55,000
Hale & Tempest
Sandoz Biosimilars – an 12 years ROI source: Pharmacloud June 2012
Hale & Tempest
India Pharma in Biosimilars
source: Citi Research August 2013
Hale & Tempest
BiosimiIar Challenges for CEOs Do I enter or keep out?
Rituximab >100 patient CT for Roche, >600 patient CT for Generic companies
Interchangeability (AB rating) unlikely Cabilly patents may delay US mAbs EU mAb in 2013 from Hospira/Celltrion EPO biosimilar side effects in Thailand Many biosimilar manufacturers in China but
few will reach EU/USA Scientifically challenging - Amgen Biobetters need a full dossier with health
economic data
Hale & Tempest
Biosimilar Alliances – to share the risk
Cipla & Biomab, China $165m 12 products Richter & Stada – mABs Celltrion, Korea -Hospira, Egis, Hikma, BB, etc Biocon & Mylan, USA, mABs: Xbiotech Teva & Lonza, EU – dissolved July 2013 Biocon Idec & Samsung, Japan – now Merck Watson & Amgen, USA Fuji Film & Kyowa Hakko Kirin DRL & Merck-Serono, Germany – mABs Bionovis (Brazil) & Merck Serono - 6
Hale & Tempest
NIBS (tyrosine kinase inhibitors)Will these small molecules replace mAbs?
Axitinib, Pfizer, cancer Cediranib, AZ, cancer Pazopanib, GSK, cancer Regorafenib, Bayer, cancer Semaxanib, Sugen, cancer Sorafenib, Bayer(Nexavar),cancer Sunitinib, Pfizer, cancer Toceranib, Pfizer, cancer Vandetanib, AZ, cancer
Tofactinib, Pfizer, RA
Hale & Tempest
BTD : Breakthrough Therapy Designationsource: Evaluate,FDA Jan 2014 31 products in 2013 6 ibs & 3 mabs J&J 4, GSK 3, Nov 3, smaller cos 12